Now present in 46 countries, with launches in 9 countries
HK inno.N's K-CAB Receives Approval in Malaysia
HK inno.N's novel drug for gastroesophageal reflux disease (GERD), K-CAB, has received marketing approval in Malaysia. HK inno.N announced on the 26th that K-CAB tablets (ingredient: Tegoprazan) were…